Document registry — page 31
Every document the Institute has published, 1,639 in total, with its identifier, type, certainty rating and review date.
Documents
-
Randomised, double-blind, placebo-controlled, phase 3 study of Semaglutide in cardiovascular and type 2 diabetes over as stated in the parent protocol. The Institute…
Very low29 Feb 2024 -
Observational, phase 2 study of Pramlintide in obesity over as stated in the parent protocol. The Institute holds no reported primary result for this record and…
Very low29 Feb 2024 -
Randomised, double-blind, placebo-controlled, phase 3 study of Liraglutide in cardiovascular and type 2 diabetes over as stated in the parent protocol. The Institute…
Very low27 Feb 2024 -
Phase 1 ascending dose, phase 1 study of Lixisenatide in type 2 diabetes over as stated in the parent protocol. The Institute holds no reported primary result for this…
Very low27 Feb 2024 -
Phase 1 ascending dose, phase 1 study of GHK-Cu in wound healing over as stated in the parent protocol. The Institute holds no reported primary result for this record…
Very low26 Feb 2024 -
Randomised, double-blind, placebo-controlled, phase 3 study of Exenatide in type 2 diabetes over as stated in the parent protocol. The Institute holds no reported…
Very low25 Feb 2024 -
Randomised withdrawal, phase 3 study of Semaglutide in obesity randomising 803 participants over 48 weeks after a 20-week run-in. Primary result: Continued treatment…
High24 Feb 2024 -
Randomised, double-blind, active-controlled, phase 3 study of Dulaglutide in type 2 diabetes randomising 1,842 participants over 36 weeks. Primary result: Dose-dependent…
High23 Feb 2024 -
Event-driven cardiovascular outcome trial, phase 3 study of Exenatide in cardiovascular and chronic kidney disease and type 2 diabetes randomising 4,076 participants…
Moderate21 Feb 2024 -
Randomised, double-blind, placebo-controlled, phase 3 study of Thymosin alpha-1 in immune modulation over as stated in the parent protocol. The Institute holds no…
Very low21 Feb 2024 -
Randomised, double-blind, placebo-controlled, phase 3 study of Teduglutide in mucosal barrier over as stated in the parent protocol. The Institute holds no reported…
Very low21 Feb 2024 -
Event-driven cardiovascular outcome trial, phase 3 study of Dulaglutide in cardiovascular and type 2 diabetes randomising 9,901 participants over median 5.4 years…
High20 Feb 2024 -
Randomised, double-blind, placebo-controlled, phase 3 study of Liraglutide in prediabetes and obesity over as stated in the parent protocol. The Institute holds no…
Very low20 Feb 2024 -
Randomised, double-blind, placebo-controlled, phase 2 study of Pramlintide in obesity over as stated in the parent protocol. The Institute holds no reported primary…
Very low20 Feb 2024 -
Randomised, double-blind, placebo-controlled, phase 3 study of Dulaglutide in type 2 diabetes over as stated in the parent protocol. The Institute holds no reported…
Very low20 Feb 2024 -
Phase 1 ascending dose, phase 1 study of Retatrutide in type 2 diabetes over as stated in the parent protocol. The Institute holds no reported primary result for this…
Very low19 Feb 2024 -
Observational, phase 3 study of PT-141 (bremelanotide) in sexual dysfunction over as stated in the parent protocol. The Institute holds no reported primary result for…
Very low19 Feb 2024 -
Randomised, double-blind, placebo-controlled, phase 2 study of AOD-9604 in knee osteoarthritis over 12 weeks. Primary result: No consistent benefit demonstrated.
Low18 Feb 2024 -
Randomised crossover, phase 1 study of Lixisenatide in type 2 diabetes over as stated in the parent protocol. The Institute holds no reported primary result for this…
Very low17 Feb 2024 -
Single-arm open-label, phase 2 study of Kisspeptin-10 in sexual dysfunction over open-label extension of the parent trial. The Institute holds no reported primary result…
Very low16 Feb 2024 -
Randomised, double-blind, placebo-controlled, phase 3 study of Tirzepatide in obesity randomising 2,539 participants over 72 weeks. Primary result: Mean change −20.9 %…
High15 Feb 2024 -
Observational, phase 2 study of Glutathione in cognition over as stated in the parent protocol. The Institute holds no reported primary result for this record and…
Very low13 Feb 2024 -
Randomised, double-blind, placebo-controlled, phase 3 study of Semaglutide, oral in type 2 diabetes over as stated in the parent protocol. The Institute holds no…
Very low11 Feb 2024 -
Randomised crossover, phase 1 study of Tirzepatide in type 2 diabetes and cardiovascular over as stated in the parent protocol. The Institute holds no reported primary…
Very low11 Feb 2024 -
Randomised, double-blind, placebo-controlled, phase 3 study of Hexarelin in lean-mass preservation over as stated in the parent protocol. The Institute holds no reported…
Very low10 Feb 2024 -
Randomised, double-blind, placebo-controlled, phase 2b study of Larazotide acetate in mucosal barrier randomising 342 participants over 12 weeks. Primary result: A…
Moderate09 Feb 2024 -
Observational, phase 3 study of Semaglutide in type 2 diabetes over as stated in the parent protocol. The Institute holds no reported primary result for this record and…
Very low09 Feb 2024 -
Randomised, double-blind, placebo-controlled, phase 3 study of Semaglutide, oral in type 2 diabetes over as stated in the parent protocol. The Institute holds no…
Very low08 Feb 2024 -
Randomised crossover, phase 1 study of CJC-1295 in gh axis over as stated in the parent protocol. The Institute holds no reported primary result for this record and…
Very low08 Feb 2024 -
Randomised crossover, phase 1 study of Lixisenatide in type 2 diabetes over as stated in the parent protocol. The Institute holds no reported primary result for this…
Very low07 Feb 2024 -
Phase 1 ascending dose, phase 1 study of Liraglutide in adolescent obesity over as stated in the parent protocol. The Institute holds no reported primary result for this…
Very low06 Feb 2024 -
Diagnostic accuracy, phase 1 study of Kisspeptin-10 in gh axis over single test. Primary result: A reproducible luteinising-hormone response used as a research probe of…
Low05 Feb 2024 -
Randomised, double-blind, placebo-controlled, phase 2 study of CagriSema (cagrilintide with semaglutide) in type 2 diabetes and obesity over as stated in the parent…
Very low05 Feb 2024 -
Randomised, double-blind, placebo-controlled, phase 2 study of Thymosin beta-4 in wound healing over as stated in the parent protocol. The Institute holds no reported…
Very low05 Feb 2024 -
Randomised, double-blind, placebo-controlled, phase 3 study of SS-31 (elamipretide) in mitochondrial disease randomising 218 participants over 24 weeks. Primary result…
Moderate02 Feb 2024 -
Randomised crossover, phase 1 study of Lixisenatide in cardiovascular and type 2 diabetes over as stated in the parent protocol. The Institute holds no reported primary…
Very low01 Feb 2024 -
Use alongside insulin in autoimmune diabetes, where the therapeutic target is postprandial excursion, insulin dose or weight rather than endogenous insulin secretion.
30 Jan 2024 -
GLP-2 receptor agonist. GLP-2 receptor agonism promotes intestinal mucosal growth, increases villus height and crypt depth, slows gastric emptying and reduces intestinal…
Moderate30 Jan 2024 -
Randomised, double-blind, placebo-controlled, phase 3 study of Exenatide in cardiovascular and chronic kidney disease and type 2 diabetes over as stated in the parent…
Very low29 Jan 2024 -
Randomised crossover, phase 1 study of GHK-Cu in wound healing over as stated in the parent protocol. The Institute holds no reported primary result for this record and…
Very low29 Jan 2024
page 31 of 41